Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836845 plus exemestane and everolimus versus exemestane and everolimus in HR-positive/HER2-negative advanced breast cancer
2013-001110-15Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing BI 836845 + exemestane + everolimus with Exemestane + everolimus (2 arms). Primary endpoint: Progression-free survival. Started Feb 2014; status: completed.
02
Drugs
xentuzumabexemestaneeverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001110-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001110-15.